Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

This study is testing the combination of cabozantinib and atezolizumab (a targeted therapy and an immunotherapy) in men with metastatic castration-resistant prostate cancer — meaning the cancer has spread and continues to grow despite hormone-lowering therapy. **You may be eligible if...** - You are a man aged 18 or older - You have confirmed prostate adenocarcinoma that has spread beyond the pelvis - Your cancer has progressed despite androgen deprivation therapy (ADT) and at least one newer hormonal therapy (e.g., enzalutamide, abiraterone, apalutamide, darolutamide) - Your testosterone levels remain very low (castrate level) - Your blood counts, kidney, and liver function are within acceptable ranges **You may NOT be eligible if...** - You have small cell prostate cancer - You have active autoimmune conditions requiring treatment - You have serious heart disease or recent blood clots - You are unable to take oral medications Talk to your doctor to see if this trial is right for you.